Inovio Pharmaceuticals (INO) news

Inovio 2Q R&D expenses $10.8M vs $14.5M Y/Y

Inovio 2Q loss/share 7.0c vs. loss/share 61c y/y

INOVIO Pharmaceuticals, Inc. (NASDAQ: INO) reported a net loss of $35.5 million for the second quarter of 2023, representing a loss per share of $0.13, compared to net loss of $108.5 million , or $0.46 per share, for the same period in 2022. The reduction in losses reflects a strategic shift in the…

Inovio Pharmaceuticals cash, equivalents $36.7M as of June 30

As of June 30, 2026, Inovio Pharmaceuticals reported holding $36.7 million in cash and cash equivalents[1]. This figure reflects the company’s liquidity position at the end of the second quarter and may be relevant to investors assessing the firm’s financial flexibility and operational capacity.…

Inovio to offer shares of common stock, accompanying warranties

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO) announced on April 1, 2026, its intention to conduct an underwritten public offering of shares of its common stock, along with accompanying Series A and Series B warrants to purchase additional shares of common stock. The offering, which is subject to…

Inovio Pharmaceuticals - May offer up to $300 mln of securities - SEC filing

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO) has announced its intention to offer and sell up to $300 million in securities, including shares of its common stock and accompanying Series A and Series B warrants to purchase additional shares of common stock, in an underwritten public offering. The…